Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04438083
Title A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors CRISPR Therapeutics AG
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | CAN | AUS


No variant requirements are available.